Unger F, Walch C, Haselsberger K, Papaefthymiou G, Trummer M, Eustacchio S, Pendl G
Department of Neurosurgery, Karl-Franzens University, Graz, Austria.
Acta Neurochir (Wien). 1999;141(12):1281-5; discussion 1285-6. doi: 10.1007/s007010050431.
From April 1992 till December 1998 stereotactic radiosurgery (Gamma Knife) was applied to 192 patients with vestibular schwannomas. 56 of them had radiosurgery as primary treatment modality and were followed-up for at least 4 years (48-80 months, median 62). Without fatal complications, control of tumour growth was achieved in all but three cases, useful hearing being preserved in more than one half of the patients (62%). The neurological state improved in 30 patients (54%). Irradiation-associated adverse effects (18%) comprised neurological signs (incomplete facial palsy, four cases (two recovered completely), and mild trigeminal neuropathy, three cases, respectively) and morphological changes (three patients) marked by an enlargement of pre-existing cystic components calling for additional surgical treatment: Microsurgical decompression was performed in two cases, the third patient underwent a shunting procedure because of hydrocephalus formation. Based on the present data, radiosurgery represents an effective treatment for vestibular schwannomas associated with an exceptionally low mortality rate and a good quality of life. With respect to the preservation of cranial nerve function, results are comparable to microsurgical resection. A short duration of hospitalization and a quick return to normal activities constitute further advantages and contribute to cost effectiveness in public health care.
1992年4月至1998年12月期间,对192例前庭神经鞘瘤患者实施了立体定向放射外科治疗(伽玛刀)。其中56例将放射外科作为主要治疗方式,并进行了至少4年的随访(48 - 80个月,中位时间62个月)。无一例出现致命并发症,除3例患者外,其余所有患者的肿瘤生长均得到控制,超过半数患者(62%)的有用听力得以保留。30例患者(54%)的神经状态有所改善。与放疗相关的不良反应(18%)包括神经体征(不完全性面瘫4例(2例完全恢复),轻度三叉神经病变各3例)和形态学改变(3例患者),表现为原有囊性成分增大,需要额外的手术治疗:2例行显微手术减压,第3例患者因形成脑积水而接受分流手术。基于目前的数据,放射外科是治疗前庭神经鞘瘤的一种有效方法,死亡率极低,生活质量良好。在保留颅神经功能方面,结果与显微手术切除相当。住院时间短和能迅速恢复正常活动是另外的优势,有助于公共卫生保健的成本效益。